Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...

“This is a relatively new adverse event, and not much is known about it,” he said. “Questions about who is most at risk and whether the hair loss will reverse upon stopping the drug can be ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

The new generation of weight-loss drugs are a boon for the overweight, but they also promise to change our relationship with ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent years, a new study says. The number of people without diabetes taking a ...

Novo Nordisk to Pay $2 Billion for New Weight Loss Drug TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion ...

revealed data showing that its new weight-loss drug candidate showed "superior" results compared with taking nothing, but fell short of the expectations. The company said a Phase 3 trial showed ...

It is also approved for similar trials in the U.S. The deal comes as Novo Nordisk works to expand its lineup of advanced weight-loss treatments. Although the company’s drugs have been popular ...